Mustang Bio Files S-1 for Undetermined Securities Offering
Ticker: MBIO · Form: S-1 · Filed: Jul 19, 2024 · CIK: 1680048
Sentiment: neutral
Topics: registration-statement, securities-offering, pharmaceutical
TL;DR
Mustang Bio filing S-1 to sell shares, watch for dilution.
AI Summary
Mustang Bio, Inc. filed an S-1 registration statement on July 19, 2024, to register an indeterminate number of securities to be offered from time to time. The company, headquartered at 377 Plantation Street, Worcester, MA, is in the pharmaceutical preparations industry. Manuel Litchman, M.D. is the President and CEO.
Why It Matters
This S-1 filing indicates Mustang Bio is preparing to potentially sell more shares, which could impact its stock price and dilute existing shareholders.
Risk Assessment
Risk Level: medium — S-1 filings often precede stock offerings, which can lead to dilution and price volatility.
Key Numbers
- 333-280927 — SEC File Number (Identifies this specific registration statement)
Key Players & Entities
- Mustang Bio, Inc. (company) — Registrant
- July 19, 2024 (date) — Filing Date
- 377 Plantation Street Worcester, Massachusetts 01605 (address) — Principal Executive Offices
- Manuel Litchman, M.D. (person) — President and Chief Executive Officer
- Rakesh Gopalan (person) — Counsel
- Joseph Walsh (person) — Counsel
- Troutman Pepper Hamilton Sanders LLP (company) — Counsel
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement under the Securities Act of 1933, indicating Mustang Bio, Inc. is preparing to offer securities for sale to the public.
When was this S-1 filing submitted?
The S-1 filing was submitted to the SEC on July 19, 2024.
Who is the principal executive officer of Mustang Bio, Inc.?
Manuel Litchman, M.D. is the President and Chief Executive Officer of Mustang Bio, Inc.
What is the principal business address of Mustang Bio, Inc.?
The principal executive offices are located at 377 Plantation Street, Worcester, Massachusetts 01605.
What is the SEC file number for this registration statement?
The SEC file number for this registration statement is 333-280927.
Filing Stats: 4,433 words · 18 min read · ~15 pages · Grade level 15.5 · Accepted 2024-07-19 17:26:16
Key Financial Figures
- $0.0001 — 0 shares of our common stock, par value $0.0001 per share, issuable upon the exercise o
- $0.3400 — rted sale price of our common stock was $0.3400 per share. You are urged to obtain curr
- $386.2 million — 2024, we had an accumulated deficit of $386.2 million. Therapeutic Pipeline Therapies for
- $2.0 million — ng was awarded a grant of approximately $2.0 million from NCI of the National Institutes of
Filing Documents
- tm2419722d1_s1.htm (S-1) — 404KB
- tm2419722d1_ex5-1.htm (EX-5.1) — 17KB
- tm2419722d1_ex23-1.htm (EX-23.1) — 2KB
- tm2419722d1_ex-filingfees.htm (EX-FILING FEES) — 14KB
- tm2419722d1_sp1img001.jpg (GRAPHIC) — 3KB
- tm2419722d1img01.jpg (GRAPHIC) — 6KB
- tm2419722d1_ex5-1img01.jpg (GRAPHIC) — 7KB
- image_001.jpg (GRAPHIC) — 5KB
- image_002.jpg (GRAPHIC) — 2KB
- image_003.jpg (GRAPHIC) — 5KB
- 0001104659-24-081203.txt ( ) — 479KB
RISK FACTORS
RISK FACTORS 19 DIVIDEND POLICY 23
USE OF PROCEEDS
USE OF PROCEEDS 24 DETERMINATION OF OFFERING PRICE 25 THE SELLING STOCKHOLDERS 26 PLAN OF DISTRIBUTION 28
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 30 LEGAL MATTERS 32 EXPERTS 32 WHERE YOU CAN FIND MORE INFORMATION 33 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 34 3 ABOUT THIS PROSPECTUS This prospectus provides you with a general description of the common stock that may be resold by the Selling Stockholders. In certain circumstances, we may provide a prospectus supplement that will contain specific information about the terms of a particular offering by the Selling Stockholders. We also may provide a prospectus supplement to add information to, or update or change information contained in, this prospectus. To the extent there is a conflict between the information contained in this prospectus and any prospectus supplement, you should rely on the information in the prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date — for example, a document incorporated by reference in this prospectus or any prospectus supplement — the statement in the later-dated document modifies or supersedes the earlier statement. This prospectus and the documents incorporated by reference into this prospectus include important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus, including the documents incorporated by reference therein, in making your investment decision. You